Antibe Therapeutics (TSX:ATE) Common Stock : C$141.61 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Common Stock?

Antibe Therapeutics's quarterly common stock increased from Jun. 2023 (C$141.58 Mil) to Sep. 2023 (C$141.58 Mil) and increased from Sep. 2023 (C$141.58 Mil) to Dec. 2023 (C$141.61 Mil).

Antibe Therapeutics's annual common stock increased from Mar. 2021 (C$111.57 Mil) to Mar. 2022 (C$139.55 Mil) and increased from Mar. 2022 (C$139.55 Mil) to Mar. 2023 (C$141.49 Mil).

Antibe Therapeutics Common Stock Historical Data

The historical data trend for Antibe Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Common Stock Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Common Stock

Get a 7-Day Free Trial

36.99

49.67

111.57

139.55

141.49

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															140.87	141.49	141.58	141.58	141.61

Antibe Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines